Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1994 Dec 20;91(26):12664–12668. doi: 10.1073/pnas.91.26.12664

Potent bombesin antagonists with C-terminal Leu-psi(CH2-N)-Tac-NH2 or its derivatives.

R Z Cai 1, H Reile 1, P Armatis 1, A V Schally 1
PMCID: PMC45499  PMID: 7809097

Abstract

Various pseudononapeptide bombesin (BN)-(6-14) antagonists with a reduced peptide bond (CH2-NH) between positions 13 and 14 can suppress the mitogenic activity of BN or gastrin-releasing peptide in 3T3 fibroblast cells and small cell lung carcinoma. In the search for more potent BN antagonists, 10 modified nonapeptide BN antagonists containing N-terminal D-Phe, D-Cpa, and D- or L-Tpi and C-terminal Leu-psi(CH2-N)-Tac-NH2, Leu-psi(CH2-N)-MeTac-NH2, or Leu-psi(CH2-N)-Me2Tac-NH2 have been synthesized by incubating [13 psi 14,CH2-NH,Cys14]BN-(6-14) or [13 psi 14-CH2-NH,Pen14]BN-(6-14) with formaldehyde or acetaldehyde (Cpa = 4-chlorophenylalanine, Tac = thiazolidine-4-carboxylic acid, Tpi = 2,3,4,9-tetrahydro-1H- pyrido[3,4-b]indol-3-carboxylic acid, and Pen = penicillamine). The biological activities of these compounds were then evaluated. [D-Phe6,13 psi 14,CH2-N,Tac14]BN-(6-14) (RC-3950-II) and [D-Phe6,13 psi 14,CH2-N,Me2Tac14]BN-(6-14) (RC-3985-II) exhibited greater potency in inhibition of 125I-labeled [Tyr4]BN binding to Swiss 3T3 cells than their parent compounds [D-Phe6,13 psi 14,CH2-NH,Cys14]BN-(6-14) (RC-3950-I) and [D-Phe6,13 psi 14,CH2-NH,Pen14]BN-(6-14) (RC-3985-I). The order of binding affinities of these compounds was as follows: [13 psi 14,CH2-N,Tac14]BN-(6-14) > [13 psi 14,CH2-N,Me2Tac14]BN-(6-14) > [13 psi 14,CH2-N,MeTac14]BN-(6-14). In most cases, the analogs with C-terminal Leu-psi(CH2-N)-Tac-NH2 were also more potent growth inhibitors of 3T3 cells than compounds containing C-terminal Leu-psi(CH2-N)-Me2Tac-NH2 or Leu-psi(CH2-N)-MeTac-NH2. The best BN antagonists of this series, RC-3950-II and [D-Cpa6,13 psi 14,CH2-N,Tac14]BN- (6-14) (RC-3925-II), inhibited gastrin-releasing peptide-stimulated growth of Swiss 3T3 cells with IC50 values of 1 nM and 6 nM, respectively. Since antagonists of this class inhibit growth of various tumors in animal cancer models, some of them may have clinical applications.

Full text

PDF
12667

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cai R. Z., Radulovic S., Pinski J., Nagy A., Redding T. W., Olsen D. B., Schally A. V. Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi. Peptides. 1992 Mar-Apr;13(2):267–271. doi: 10.1016/0196-9781(92)90107-e. [DOI] [PubMed] [Google Scholar]
  2. Carney D. N., Cuttitta F., Moody T. W., Minna J. D. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res. 1987 Feb 1;47(3):821–825. [PubMed] [Google Scholar]
  3. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  4. Coy D. H., Heinz-Erian P., Jiang N. Y., Sasaki Y., Taylor J., Moreau J. P., Wolfrey W. T., Gardner J. D., Jensen R. T. Probing peptide backbone function in bombesin. A reduced peptide bond analogue with potent and specific receptor antagonist activity. J Biol Chem. 1988 Apr 15;263(11):5056–5060. [PubMed] [Google Scholar]
  5. Coy D. H., Taylor J. E., Jiang N. Y., Kim S. H., Wang L. H., Huang S. C., Moreau J. P., Gardner J. D., Jensen R. T. Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity. J Biol Chem. 1989 Sep 5;264(25):14691–14697. [PubMed] [Google Scholar]
  6. Cuttitta F., Carney D. N., Mulshine J., Moody T. W., Fedorko J., Fischler A., Minna J. D. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. 1985 Aug 29-Sep 4Nature. 316(6031):823–826. doi: 10.1038/316823a0. [DOI] [PubMed] [Google Scholar]
  7. Halmos G., Pinski J., Szoke B., Schally A. V. Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer. Cancer Lett. 1994 Sep 30;85(1):111–118. doi: 10.1016/0304-3835(94)90246-1. [DOI] [PubMed] [Google Scholar]
  8. Heimbrook D. C., Saari W. S., Balishin N. L., Friedman A., Moore K. S., Reimen M. W., Kiefer D. M., Rotberg N. S., Wallen J. W., Oliff A. Carboxyl-terminal modification of a gastrin releasing peptide derivative generates potent antagonists. J Biol Chem. 1989 Jul 5;264(19):11258–11262. [PubMed] [Google Scholar]
  9. Kris R. M., Hazan R., Villines J., Moody T. W., Schlessinger J. Identification of the bombesin receptor on murine and human cells by cross-linking experiments. J Biol Chem. 1987 Aug 15;262(23):11215–11220. [PubMed] [Google Scholar]
  10. McPherson G. A. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J Pharmacol Methods. 1985 Nov;14(3):213–228. doi: 10.1016/0160-5402(85)90034-8. [DOI] [PubMed] [Google Scholar]
  11. Milovanovic S. R., Radulovic S., Groot K., Schally A. V. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160. Prostate. 1992;20(4):269–280. doi: 10.1002/pros.2990200403. [DOI] [PubMed] [Google Scholar]
  12. Moody T. W., Kris R. M., Fiskum G., Linden C. D., Berg M., Schlessinger J. Characterization of receptors for bombesin/gastrin-releasing peptide in human and murine cells. Methods Enzymol. 1989;168:481–493. doi: 10.1016/0076-6879(89)68037-8. [DOI] [PubMed] [Google Scholar]
  13. Pinski J., Halmos G., Yano T., Szepeshazi K., Qin Y., Ertl T., Schally A. V. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. Int J Cancer. 1994 May 15;57(4):574–580. doi: 10.1002/ijc.2910570422. [DOI] [PubMed] [Google Scholar]
  14. Pinski J., Schally A. V., Halmos G., Szepeshazi K., Groot K., O'Byrne K., Cai R. Z. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice. Br J Cancer. 1994 Nov;70(5):886–892. doi: 10.1038/bjc.1994.415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Qin Y., Ertl T., Cai R. Z., Halmos G., Schally A. V. Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro. Cancer Res. 1994 Feb 15;54(4):1035–1041. [PubMed] [Google Scholar]
  16. Qin Y., Halmos G., Cai R. Z., Szoke B., Ertl T., Schally A. V. Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors. J Cancer Res Clin Oncol. 1994;120(9):519–528. doi: 10.1007/BF01221028. [DOI] [PubMed] [Google Scholar]
  17. Radulovic S., Cai R. Z., Serfozo P., Groot K., Redding T. W., Pinski J., Schally A. V. Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi. Int J Pept Protein Res. 1991 Dec;38(6):593–600. doi: 10.1111/j.1399-3011.1991.tb01545.x. [DOI] [PubMed] [Google Scholar]
  18. Radulovic S., Miller G., Schally A. V. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095). Cancer Res. 1991 Nov 1;51(21):6006–6009. [PubMed] [Google Scholar]
  19. Reile H., Armatis P. E., Schally A. V. Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells. Prostate. 1994 Jul;25(1):29–38. doi: 10.1002/pros.2990250105. [DOI] [PubMed] [Google Scholar]
  20. Rozengurt E., Sinnett-Smith J. Bombesin stimulation of DNA synthesis and cell division in cultures of Swiss 3T3 cells. Proc Natl Acad Sci U S A. 1983 May;80(10):2936–2940. doi: 10.1073/pnas.80.10.2936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sasaki Y., Coy D. H. Solid phase synthesis of peptides containing the CH2NH peptide bond isostere. Peptides. 1987 Jan-Feb;8(1):119–121. doi: 10.1016/0196-9781(87)90174-4. [DOI] [PubMed] [Google Scholar]
  22. Szepeshazi K., Schally A. V., Cai R. Z., Radulovic S., Milovanovic S., Szoke B. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters. Cancer Res. 1991 Nov 1;51(21):5980–5986. [PubMed] [Google Scholar]
  23. Szepeshazi K., Schally A. V., Halmos G., Groot K., Radulovic S. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095. J Natl Cancer Inst. 1992 Dec 16;84(24):1915–1922. doi: 10.1093/jnci/84.24.1915. [DOI] [PubMed] [Google Scholar]
  24. Wang L. H., Coy D. H., Taylor J. E., Jiang N. Y., Kim S. H., Moreau J. P., Huang S. C., Mantey S. A., Frucht H., Jensen R. T. Desmethionine alkylamide bombesin analogues: a new class of bombesin receptor antagonists with potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells. Biochemistry. 1990 Jan 23;29(3):616–622. doi: 10.1021/bi00455a004. [DOI] [PubMed] [Google Scholar]
  25. Zachary I., Rozengurt E. High-affinity receptors for peptides of the bombesin family in Swiss 3T3 cells. Proc Natl Acad Sci U S A. 1985 Nov;82(22):7616–7620. doi: 10.1073/pnas.82.22.7616. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES